ResMed (NYSE: RMD) reported Q1 EPS of $1.51, $0.15 better than the analyst estimate of $1.36. Revenue for the quarter came in at $904 million versus the consensus estimate of $860.89 million.

For earnings history and earnings-related data on ResMed (RMD) click here.